• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations

    6/2/25 7:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials
    Get the next $DHR alert in real time by email

    SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE:DHR), announces three software ecosystem enhancements at ASMS. These developments will present new ways to acquire data, new standards for performance, and new practices to extract elevated insights, all supporting the theme that "all science is data science now."

    The new SCIEX OS software version 4.0 is the latest evolution of its powerful software platform.

    This new Microsoft Windows 11 compatible release drives operability enhancements with speed and automation to improve customers' time to results. SCIEX OS 4.0 delivers advanced hardware support for the latest SCIEX innovations, including today's newly launched ZenoTOF 8600 system. In addition, automated workflow improvements and progressive software functionalities establish the benchmark for efficiency, accuracy, and precision.

    The intuitive interface empowers operators to seamlessly integrate both new and existing workflows into SCIEX OS. This enables faster deployment and improves operational readiness when compared to previous SCIEX software systems. Administrative features within SCIEX OS 4.0 boosts security and compliance to the ecosystem so labs can produce data with the highest integrity and traceability.

    AI Quantitation software ushers in a new era of artificial intelligence driven data processing automation.

    AI Quantitation software is a focused solution that eliminates data process operator bias and accelerates actionable decision-making across the absorption, distribution, metabolism, and excretion (ADME) workflows. With the power of artificial intelligence, AI Quantitation software automatically predicts the most suitable fragments for MRM analysis of new compounds or analytes and eliminates the need for time-consuming compound standard infusions and manual fragment optimization.

    The impact of AI Quantitation software reflects SCIEX and Mass Analytica's continued commitment towards drug discovery laboratories with practical, efficient tools. By integrating AI-driven automation into established workflows, this solution helps reduce manual workload, improve consistency, and support faster decision-making. Scientists can now focus more on research and less on routine data processing.

    To improve accessibility, SCIEX supports the vibrant open-source software community with SCIEX MS Data Converter 2.0.

    SCIEX strives to offer integrated SCIEX OS data processing so customers can unlock the full potential of their data, whether using open-source tools or their own data processing capabilities. Knowing the rapid innovation of the scientific community, SCIEX seeks to improve the usability, flexibility, and availability of our data to the entire community. SCIEX MS Data Converter 2.0 keeps pace with the latest software languages and ensures the highest quality of collaboration and service we strive for at SCIEX.

    "With these updates, we want to empower customers to take the next step in their LC-MS journey. We know software is a critical component of success for scientists, and the SCIEX OS ecosystem continues to prove its ability to provide the insights needed to make impactful discoveries and decisions," said Chris Lock Ph.D., Vice president of global research and development at SCIEX. "Our reoccurring theme this year is ‘prove it.' The proof is in the data, and we invite you to come explore it with us."

    About SCIEX

    SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

    Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. ​

    Advances in human wellness depend on the power of precise science.​

    For more information, visit sciex.com. ​

    Connect with us on LinkedIn, Facebook, X (Twitter) and Instagram.​

    SCIEX is proud to be part of Danaher. ​

    Danaher's science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

    The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

    Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

    © 2025 DH Tech. Dev. Pte. Ltd. MKT-35295-A.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250602267092/en/

    Lulu VanZandt

    Senior manager, brand, public relations and social media

    [email protected]

    M: +1 (508) 782-9484

    Get the next $DHR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DHR

    DatePrice TargetRatingAnalyst
    7/11/2025$275.00Sector Perform → Sector Outperform
    Scotiabank
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    3/21/2025$260.00Neutral → Buy
    Goldman
    3/14/2025$260.00Hold → Buy
    Stifel
    2/3/2025Outperform → Mkt Perform
    Raymond James
    12/23/2024Sector Perform
    Scotiabank
    12/19/2024$275.00Buy
    Guggenheim
    12/13/2024$290.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i

      6/27/25 7:35:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f

      6/27/25 7:30:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Schedules Second Quarter 2025 Earnings Conference Call

      WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

      6/17/25 4:30:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director List Teri exercised 3,928 shares at a strike of $59.34 and covered exercise/tax liability with 1,150 shares, increasing direct ownership by 13% to 23,517 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      7/7/25 5:00:12 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • New insider Milosevich Gregory M claimed ownership of 4,455 shares (SEC Form 3)

      3 - DANAHER CORP /DE/ (0000313616) (Issuer)

      7/1/25 5:00:51 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Director Stevens Raymond C was granted 577 shares, increasing direct ownership by 5% to 12,361 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      5/19/25 5:02:20 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Danaher upgraded by Scotiabank with a new price target

      Scotiabank upgraded Danaher from Sector Perform to Sector Outperform and set a new price target of $275.00

      7/11/25 7:56:02 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher upgraded by Barclays with a new price target

      Barclays upgraded Danaher from Equal Weight to Overweight and set a new price target of $205.00

      4/10/25 8:28:29 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher upgraded by Goldman with a new price target

      Goldman upgraded Danaher from Neutral to Buy and set a new price target of $260.00

      3/21/25 8:01:35 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    SEC Filings

    See more
    • SEC Form 11-K filed by Danaher Corporation

      11-K - DANAHER CORP /DE/ (0000313616) (Filer)

      6/17/25 8:19:40 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SD filed by Danaher Corporation

      SD - DANAHER CORP /DE/ (0000313616) (Filer)

      5/12/25 4:39:59 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - DANAHER CORP /DE/ (0000313616) (Filer)

      5/8/25 4:36:17 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Leadership Updates

    Live Leadership Updates

    See more
    • Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i

      6/27/25 7:35:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f

      6/27/25 7:30:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Announces Appointment of Charles Lamanna to Danaher Board

      WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud

      2/20/25 4:45:00 PM ET
      $DHR
      $MSFT
      Industrial Machinery/Components
      Industrials
      Computer Software: Prepackaged Software
      Technology

    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

      SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

      2/9/23 11:16:32 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

      SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

      2/9/22 3:43:35 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D/A filed by Danaher Corporation (Amendment)

      SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)

      11/2/21 9:29:29 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Financials

    Live finance-specific insights

    See more
    • Danaher Schedules Second Quarter 2025 Earnings Conference Call

      WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

      6/17/25 4:30:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Announces Quarterly Dividend

      WASHINGTON, May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and h

      5/6/25 4:15:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Reports First Quarter 2025 Results

      WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-

      4/22/25 6:00:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials